Michael Charles Heinrich

List of Publications by Citations

241 papers	36,386 citations	85 h-index	190 g-index
255 ext. papers	40,090 ext. citations	7.7 avg, IF	6.62 L-index

#	Paper	IF	Citations
241	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *New England Journal of Medicine*, **2002**, 347, 472-80	59.2	3474
240	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet, The*, **2006**, 368, 1329-38	40	2004
239	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *Journal of Clinical Oncology*, **2003**, 21, 4342-9	2.2	1885
238	PDGFRA activating mutations in gastrointestinal stromal tumors. *Science*, **2003**, 299, 708-10	33.3	1863
237	Biology of gastrointestinal stromal tumors. *Journal of Clinical Oncology*, **2004**, 22, 3813-25	2.2	907
236	In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Research*, **2005**, 65, 4500-5	10.1	904
235	Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood*, **2000**, 96, 925-932	2.2	878
234	Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *Journal of Clinical Oncology*, **2008**, 26, 626-32	2.2	801
233	Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *Journal of Clinical Oncology*, **2008**, 26, 620-5	2.2	781
232	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. *Blood*, **2003**, 101, 3597-605	2.2	731
231	PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *Journal of Clinical Oncology*, **2005**, 23, 5357-64	2.2	658
230	Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *Journal of Clinical Oncology*, **2006**, 24, 4764-74	2.2	652
229	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *Journal of Clinical Oncology*, **2008**, 26, 5352-9	2.2	583
228	Gastrointestinal stromal tumours: origin and molecular oncology. *Nature Reviews Cancer*, **2011**, 11, 865-78	31.3	565
227	KIT gene mutations and copy number in melanoma subtypes. *Clinical Cancer Research*, **2008**, 14, 6821-8	12.9	532
226	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. *Annals of Oncology*, **2005**, 16, 566-78	10.3	518
225	The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. *American Journal of Pathology*, **2004**, 165, 107-13	5.8	505

224	Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. *Journal of Clinical Oncology*, **2002**, 20, 1692-703	2.2	497
223	Clinical management of gastrointestinal stromal tumors: before and after STI-571. *Human Pathology*, **2002**, 33, 466-77	3.7	482
222	Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. *Journal of Clinical Oncology*, **2008**, 26, 5360-7	2.2	480
221	Gastrointestinal stromal tumour. *Lancet, The*, **2007**, 369, 1731-41	40	466
220	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *Journal of Clinical Oncology*, **2013**, 31, 3182-90	2.2	409
219	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. *Cancer Research*, **2006**, 66, 473-81	10.1	398
218	KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. *American Journal of Surgical Pathology*, **2004**, 28, 889-94	6.7	393
217	Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. *Nature Genetics*, **2013**, 45, 131-2	36.3	386
216	Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. *Journal of Clinical Oncology*, **2005**, 23, 866-73	2.2	374
215	Major response to imatinib mesylate in KIT-mutated melanoma. *Journal of Clinical Oncology*, **2008**, 26, 2046-51	2.2	373
214	KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. *American Journal of Pathology*, **2002**, 160, 1567-72	5.8	366
213	Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. *Human Pathology*, **2002**, 33, 484-95	3.7	365
212	A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. *American Journal of Surgical Pathology*, **2008**, 32, 210-8	6.7	350
211	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. *Blood*, **2005**, 106, 3377-9	2.2	319
210	Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. *Journal of Surgical Oncology*, **2009**, 99, 42-7	2.8	296
209	Activating alleles of JAK3 in acute megakaryoblastic leukemia. *Cancer Cell*, **2006**, 10, 65-75	24.3	265
208	KIT mutations are common in testicular seminomas. *American Journal of Pathology*, **2004**, 164, 305-13	5.8	258
207	Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood*, **2000**, 96, 925-32	2.2	256

206	Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *Journal of Clinical Oncology*, **2006**, 24, 1195-203	2.2	248
205	Molecular pathobiology of gastrointestinal stromal sarcomas. *Annual Review of Pathology: Mechanisms of Disease*, **2008**, 3, 557-86	34	239
204	Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. *Blood*, **2006**, 108, 3674-81	2.2	224
203	An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. *Clinical Cancer Research*, **2003**, 9, 5465-76	12.9	221
202	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. *Journal of Clinical Investigation*, **2004**, 114, 379-88	15.9	218
201	Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*, **2005**, 106, 2865-70	2.2	211
200	MicroRNA expression signature of human sarcomas. *Oncogene*, **2008**, 27, 2015-26	9.2	199
199	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia*, **2005**, 19, 1536-42	10.7	199
198	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. *Journal of Clinical Oncology*, **2014**, 32, 1563-70	2.2	192
197	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. *Journal of Clinical Oncology* , **2012**, 30, 2401-7	2.2	192
196	Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. *Clinical Cancer Research*, **2009**, 15, 7510-7518	12.9	165
195	Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. *Clinical Cancer Research*, **2012**, 18, 4375-84	12.9	164
194	Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. *Journal of Clinical Oncology*, **2008**, 26, 4659-65	2.2	163
193	SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. *Blood*, **2002**, 100, 2941-9	2.2	162
192	STI571: a paradigm of new agents for cancer therapeutics. *Journal of Clinical Oncology*, **2002**, 20, 325-34	2.2	159
191	Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clinical Cancer Research*, **2008**, 14, 2717-25	12.9	154
190	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer Cell*, **2007**, 12, 501-13	24.3	154
189	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. *Modern Pathology*, **2008**, 21, 476-84	9.8	148

188	Absence of BRAF and NRAS mutations in uveal melanoma. *Cancer Research*, **2003**, 63, 5761-6	10.1	145
187	Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. *Annals of Surgical Oncology*, **2012**, 19, 1074-80	3.1	138
186	Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. *Cancer Research*, **2007**, 67, 9084-8	10.1	136
185	Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. *Blood*, **2010**, 115, 2372-9	2.2	135
184	Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. *Journal of Clinical Oncology*, **2005**, 23, 2735-43	2.2	129
183	SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. *Journal of the National Cancer Institute*, **2011**, 103, 983-7	9.7	125
182	Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. *Pediatric Blood and Cancer*, **2009**, 52, 767-71	3	124
181	Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. *Oncogene*, **2004**, 23, 7780-90	9.2	121
180	Imatinib targeting of KIT-mutant oncoprotein in melanoma. *Clinical Cancer Research*, **2008**, 14, 7726-32	12.9	116
179	Kaposi© sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. *Journal of Virology*, **2002**, 76, 8383-99	6.6	115
178	Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clinical Cancer Research*, **2009**, 15, 5902-9	12.9	114
177	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. *New England Journal of Medicine*, **2019**, 381, 2315-2326	59.2	114
176	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. *Journal of Translational Medicine*, **2016**, 14, 339	8.5	113
175	Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. *Clinical Cancer Research*, **2014**, 20, 5745-5755	12.9	113
174	Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. *Blood*, **2004**, 104, 4202-9	2.2	108
173	Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. *Journal of Molecular Diagnostics*, **2013**, 15, 171-6	5.1	107
172	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 923-934	21.7	102
171	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. *Lancet Oncology, The*, **2020**, 21, 935-946	21.7	101

170	Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). *Cancer Research*, **2004**, 64, 5127-31	10.1	101
169	Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. *Clinical Cancer Research*, **2007**, 13, 5398-405	12.9	100
168	High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. *The Hematology Journal*, **2004**, 5, 55-60		100
167	High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. *Blood*, **2009**, 113, 1749-55	2.2	97
166	Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. *Breast Cancer Research and Treatment*, **2010**, 120, 409-18	4.4	97
165	Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. *Journal of Surgical Oncology*, **2005**, 90, 195-207; discussion 207	2.8	94
164	Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. *Cancer*, **2001**, 93, 269-75	6.4	94
163	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. *Cancer Cell*, **2019**, 35, 738-751.e9	24.3	93
162	A precision therapy against cancers driven by mutations. *Science Translational Medicine*, **2017**, 9,	17.5	91
161	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. *Clinical Cancer Research*, **2015**, 21, 2289-96	12.9	90
160	High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. *Modern Pathology*, **2010**, 23, 27-37	9.8	90
159	RNAi screen for rapid therapeutic target identification in leukemia patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 8695-700	11.5	88
158	Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. *Clinical Cancer Research*, **2005**, 11, 6987-93	12.9	88
157	M□□rier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. *Journal of Clinical Investigation*, **2007**, 117, 70-80	15.9	86
156	"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. *American Journal of Surgical Pathology*, **2011**, 35, 495-504	6.7	85
155	Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2006**, 29, 12-3	2.7	85
154	Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Molecular Cancer*, **2013**, 12, 19	42.1	80
153	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. *Blood*, **2008**, 111, 4788-96	2.2	77

152	BRAF in papillary thyroid carcinoma of ovary (struma ovarii). *American Journal of Surgical Pathology*, **2007**, 31, 1337-43	6.7	75
151	Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. *Histopathology*, **2012**, 61, 801-9	7.3	74
150	Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. *Medical Oncology*, **2012**, 29, 1765-72	3.7	72
149	A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 495-9	2.7	72
148	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. *Laboratory Investigation*, **2010**, 90, 1285-94	5.9	71
147	The Fanconi Anemia Group C Gene Product Is Located in Both the Nucleus and Cytoplasm of Human Cells. *Blood*, **1998**, 91, 1418-1425	2.2	71
146	Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. *Leukemia*, **2007**, 21, 489-93	10.7	69
145	Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. *Journal of Molecular Diagnostics*, **2011**, 13, 504-13	5.1	68
144	Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. *Blood*, **2004**, 104, 3754-7	2.2	68
143	Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. *American Journal of Surgical Pathology*, **2005**, 29, 1680-3	6.7	68
142	Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. *International Journal of Cancer*, **2009**, 125, 2991-4	7.5	66
141	Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. *Cancer Research*, **2015**, 75, 880-91	10.1	64
140	Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. *International Journal of Gynecological Pathology*, **2006**, 25, 288-92	3.2	64
139	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. *Cancer Cell*, **2019**, 36, 431-443.e5	24.3	63
138	MET receptor sequence variants R970C and T992I lack transforming capacity. *Cancer Research*, **2010**, 70, 6233-7	10.1	63
137	Biology of gastrointestinal stromal tumors: KIT mutations and beyond. *Cancer Investigation*, **2004**, 22, 106-16	2.1	63
136	Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. *Cancer Chemotherapy and Pharmacology*, **2003**, 51, 261-5	3.5	63
135	Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. *Annals of Oncology*, **2016**, 27, 1794-9	10.3	63

134	Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. *Leukemia Research*, **2009**, 33, 735-41	2.7	62
133	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. *Blood*, **2008**, 111, 2238-45	2.2	62
132	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. *British Journal of Cancer*, **2019**, 120, 612-620	8.7	62
131	Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. *Cancer Medicine*, **2015**, 4, 101-3	4.8	61
130	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). *BMC Cancer*, **2014**, 14, 685	4.8	61
129	Gastrointestinal stromal tumors. *Current Treatment Options in Oncology*, **2001**, 2, 485-91	5.4	59
128	DNA Cross-Linker□Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. *Blood*, **1998**, 91, 275-287	2.2	59
127	A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. *Leukemia*, **2010**, 24, 44-50	10.7	58
126	The gene expression profile of extraskeletal myxoid chondrosarcoma. *Journal of Pathology*, **2005**, 206, 433-44	9.4	58
125	Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. *Molecular Cancer Therapeutics*, **2012**, 11, 1770-80	6.1	55
124	Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. *Leukemia*, **2004**, 18, 864-71	10.7	55
123	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2007-18	3.4	52
122	In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. *Blood*, **2005**, 106, 227-34	2.2	52
121	Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. *Leukemia Research*, **2006**, 30, 1097-104	2.7	51
120	Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. *Leukemia*, **2012**, 26, 2144-6	10.7	50
119	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. *JAMA Oncology*, **2017**, 3, 944-952	13.4	49
118	Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. *Blood*, **2004**, 103, 2929-35	2.2	49
117	Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1. *Journal of Medical Genetics*, **2007**, 44, e61	5.8	48

116	Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. *Annals of Oncology*, **2003**, 14, 873-80	10.3	48
115	Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. *Molecular Cancer*, **2013**, 12, 46	42.1	46
114	Survey of activated FLT3 signaling in leukemia. *PLoS ONE*, **2011**, 6, e19169	3.7	46
113	Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation. *American Journal of Surgical Pathology*, **2010**, 34, 907-12	6.7	46
112	Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. *Molecular Cancer Therapeutics*, **2009**, 8, 2172-82	6.1	45
111	KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. *Journal of Molecular Diagnostics*, **2004**, 6, 366-70	5.1	44
110	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. *BMC Cancer*, **2016**, 16, 22	4.8	43
109	Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. *Blood*, **2004**, 104, 2912-8	2.2	43
108	Gastrointestinal stromal tumors: molecular markers and genetic subtypes. *Hematology/Oncology Clinics of North America*, **2013**, 27, 871-88	3.1	42
107	A human gene coding for a membrane-associated nucleic acid-binding protein. *Journal of Biological Chemistry*, **2000**, 275, 33655-62	5.4	41
106	Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. *Cancer*, **2007**, 110, 2507-10	6.4	40
105	KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. *Journal of Clinical Oncology*, **2015**, 33, e93-6	2.2	39
104	Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. *Blood*, **2000**, 96, 925-932	2.2	39
103	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. *Nature Communications*, **2017**, 8, 14674	17.4	38
102	A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. *Blood*, **2007**, 110, 323-33	2.2	38
101	FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). *Leukemia*, **2006**, 20, 2008-14	10.7	36
100	RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. *Blood*, **2005**, 105, 2952-4	2.2	36
99	Immunohistochemical and molecular markers in breast phyllodes tumors. *Applied Immunohistochemistry and Molecular Morphology*, **2011**, 19, 119-25	1.9	35

98	Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. *American Journal of Hypertension*, **2012**, 25, 1118-23	2.3	35
97	Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. *Journal of the American Academy of Dermatology*, **2014**, 71, 229-36	4.5	32
96	Metastatic intravagal paraganglioma. Case report and review of the literature. *American Journal of Medicine*, **1985**, 78, 1017-24	2.4	32
95	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. *Journal of Clinical Oncology*, **2020**, 38, 3294-3303	2.2	31
94	Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. *Journal of Molecular Diagnostics*, **2006**, 8, 604-12	5.1	29
93	Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. *Endocrine Pathology*, **2010**, 21, 73-9	4.2	28
92	An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. *Leukemia*, **2008**, 22, 2269-72	10.7	28
91	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. *Blood*, **2005**, 106, 3532-7	2.2	28
90	The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific. *Journal of Biological Chemistry*, **2002**, 277, 26327-34	5.4	28
89	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. *Future Oncology*, **2020**, 16, 4251-4264	3.6	28
88	Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. *Oncology Reports*, **2007**, 18, 9-15	3.5	28
87	Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update. *Seminars in Diagnostic Pathology*, **2015**, 32, 392-9	4.3	27
86	The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. *Cell Cycle*, **2009**, 8, 2621-30	4.7	26
85	Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. *Cancer Medicine*, **2013**, 2, 21-31	4.8	25
84	Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. *Dermatologic Surgery*, **2006**, 32, 456-9	1.7	25
83	Retroviral-Mediated Gene Transduction of c-kit Into Single Hematopoietic Progenitor Cells From Cord Blood Enhances Erythroid Colony Formation and Decreases Sensitivity to Inhibition by Tumor Necrosis Factor-? and Transforming Growth Factor-?. *Blood*, **1999**, 94, 2319-2332	2.2	25
82	Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. *American Journal of Hematology*, **2004**, 75, 142-5	7.1	24
81	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. *European Journal of Cancer*, **2021**, 145, 132-142	7.5	24

80	Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.. *Blood*, **2004**, 104, 1792-1792	2.2	23
79	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. *Cancer Discovery*, **2021**, 11, 108-125	24.4	23
78	A functional genomics approach to Kaposi sarcoma. *Annals of the New York Academy of Sciences*, **2002**, 975, 180-91	6.5	22
77	Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. *Histopathology*, **2011**, 59, 1071-80	7.3	21
76	Epidemiology of GIST. *American Journal of Gastroenterology*, **2005**, 100, 2366	0.7	21
75	Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. *Pharmacology & Therapeutics*, **2018**, 191, 123-134	13.9	21
74	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	19
73	Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. *Clinical Cancer Research*, **2020**, 26, 1837-1845	12.9	19
72	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. *European Journal of Cancer*, **2016**, 61, 94-101	7.5	19
71	Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. *Oncotarget*, **2016**, 7, 41390-41403	3.3	19
70	The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3-dependent pathway. *Molecular Cancer Therapeutics*, **2011**, 10, 949-59	6.1	18
69	Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. *Expert Review of Molecular Diagnostics*, **2017**, 17, 445-457	3.8	17
68	Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 481-9	6.1	17
67	Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. *Journal of Urology*, **2006**, 175, 53-6	2.5	17
66	A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. *Leukemia*, **2005**, 19, 1859-62	10.7	17
65	SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. *BMC Medical Genetics*, **2015**, 16, 87	2.1	16
64	Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. *Clinical Cancer Research*, **2014**, 20, 1306-12	12.9	16
63	Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. *Human Pathology*, **2012**, 43, 2167-76	3.7	16

62	Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures. *Journal of Cellular Physiology*, **1995**, 165, 386-97	7	16
61	A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.. *Journal of Clinical Oncology*, **2014**, 32, 10506-10506	2.2	16
60	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. *Molecular Cancer Therapeutics*, **2019**, 18, 1985-1996	6.1	15
59	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. *Journal of Clinical Oncology*, **2017**, 35, 11011-11011	2.2	15
58	Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia. *British Journal of Haematology*, **2005**, 130, 801-3	4.5	14
57	Regorafenib for treatment of advanced gastrointestinal stromal tumors. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 549-58	4	13
56	Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. *Haematologica*, **2009**, 94, 46-53	6.6	13
55	Clinical activity of avapritinib in fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).. *Journal of Clinical Oncology*, **2019**, 37, 11022-11022	2.2	13
54	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma. *Oncotarget*, **2019**, 10, 1850-1859	3.3	12
53	Imatinib treatment of metastatic GIST: don't stop (believing). *Lancet Oncology, The*, **2010**, 11, 910-1	21.7	12
52	LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. *Oncogene*, **2019**, 38, 1200-1210	9.2	12
51	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. *Journal of Clinical Oncology*, **2021**, 39, 3128-3139	2.2	12
50	Is KIT an important therapeutic target in small cell lung cancer?. *Clinical Cancer Research*, **2003**, 9, 5825-8	12.9	12
49	Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. *Clinical Sarcoma Research*, **2019**, 9, 4	2.5	11
48	Genomic aberrations in cell cycle genes predict progression of -mutant gastrointestinal stromal tumors (GISTs). *Clinical Sarcoma Research*, **2019**, 9, 3	2.5	11
47	Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects. *Mini-Reviews in Medicinal Chemistry*, **2004**, 4, 255-71	3.2	11
46	S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors. *Oncologist*, **2015**, 20, 1353-4	5.7	9
45	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study.. *Journal of Clinical Oncology*, **2017**, 35, TPS11080-TPS11080	2.2	9

44	Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. *Clinical Cancer Research*, **2017**, 23, 6733-6743	12.9	8
43	Molecular basis for treatment of gastrointestinal stromal tumours. *European Journal of Cancer, Supplement*, **2006**, 4, 10-18	1.6	8
42	Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus. *Blood*, **2006**, 107, 3114-21	2.2	8
41	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. *Oncogene*, **2021**, 40, 1957-1973	9.2	8
40	Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases. *Histopathology*, **2017**, 71, 805-812	7.3	7
39	A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin. *Journal of Pathology*, **2020**, 252, 441-450	9.4	7
38	Posttranscriptional cell cycle-dependent regulation of human FANCC expression. *Blood*, **2000**, 95, 3970-7	2.2	7
37	PDGFRA Antibody for Soft Tissue Sarcoma. *Cell*, **2017**, 168, 555	56.2	6
36	Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity. *Molecular Cancer Therapeutics*, **2014**, 13, 2840-51	6.1	6
35	Co-transduction of cDNAs for c-kit and steel factor into single CD34+ cord blood cells further enhances the growth of erythroid and multipotential progenitors. *Journal of Hematotherapy and Stem Cell Research*, **2000**, 9, 813-25		6
34	Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. *Frontiers in Oncology*, **2021**, 11, 672500	5.3	6
33	New treatment strategies for advanced-stage gastrointestinal stromal tumours.. *Nature Reviews Clinical Oncology*, **2022**,	19.4	6
32	Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. *BMC Cancer*, **2021**, 21, 291	4.8	5
31	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. *Leukemia and Lymphoma*, **2019**, 60, 2384-2393	1.9	4
30	Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas. *Cancer Treatment and Research*, **2004**, 120, 129-50	3.5	4
29	PHASE 2 STUDY OF PONATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EFFICACY, SAFETY, AND IMPACT OF LIQUID BIOPSY AND OTHER BIOMARKERS.. *Clinical Cancer Research*, **2022** ,	12.9	4
28	Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.. *Journal of Clinical Oncology*, **2016**, 34, e22520-e22520	2.2	4
27	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Mutations in the Phase III INVICTUS Study. *Clinical Cancer Research*, **2021**, 27, 6333-6342	12.9	4

26	Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment. *JCI Insight*, **2021**, 6,	9.9	4
25	Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting. *JAMA Oncology*, **2017**, 3, 597-599	13.4	3
24	Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: A report of three new cases with mutational analysis and comparative genomic hybridization. *Oncology Reports*, **2007**,	3.5	3
23	Does tumor mutational status correlate with clinical response to imatinib?. *Nature Clinical Practice Oncology*, **2006**, 3, 600-1		3
22	Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.. *Journal of Clinical Oncology*, **2018**, 36, 11511-11511	2.2	3
21	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. *Oncologist*, **2021**, 26, e2053-e2060	5.7	3
20	Tandutinib (MLN518), a Potent FLT3 Inhibitor, Synergizes with Cytarabine and/or Daunorubicin in a Sequence-Independent Manner.. *Blood*, **2006**, 108, 1374-1374	2.2	2
19	Combining the Allosteric ABL1 Tyrosine Kinase Inhibitor ABL001 with ATP-Competitive Inhibitors to Suppress Resistance in Chronic Myeloid Leukemia. *Blood*, **2016**, 128, 2747-2747	2.2	2
18	Management of tyrosine kinase inhibitor-resistant gastrointestinal stromal tumors. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 663-8	7.1	2
17	Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval. *Journal of Clinical Oncology*, **2021**, 39, 1674-1686	2.2	2
16	Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. *Clinical Cancer Research*, **2021**,	12.9	2
15	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. *European Journal of Cancer*, **2021**, 155, 236-244	7.5	2
14	Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes. *Leukemia and Lymphoma*, **2020**, 61, 2511-2514	1.9	1
13	Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.. *Blood*, **2004**, 104, 2091-2091	2.2	1
12	In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.. *Blood*, **2005**, 106, 434-434	2.2	1
11	FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.. *Blood*, **2009**, 114, 1740-1740	2.2	1
10	Gastrointestinal stromal tumours: origin and molecular oncology		1
9	Disease-free Interval Is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor. *Annals of Surgical Oncology*, **2021**, 28, 7912-7920	3.1	1

8	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.. *BMC Cancer*, **2022**, 22, 511	4.8	1
7	CKIT **2017**, 683-692		
6	A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.. *Blood*, **2005**, 106, 1530-1530	2.2	
5	A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.. *Blood*, **2006**, 108, 2334-2334	2.2	
4	CKIT **2015**, 1-9		
3	Combination Therapy In Mast Cell Neoplasms: Co-Targeting KIT and NFAT Signaling Pathways. *Blood*, **2013**, 122, 4105-4105	2.2	
2	Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?. *Surgery*, **2021**, 170, 1481-1486	3.6	
1	Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors. *Expert Opinion on Orphan Drugs*, **2016**, 4, 659-670	1.1	